multimmune GmbH

What multimmune GmbH does

multimmune GmbH is a private, clinical-stage biopharmaceutical company founded in 1999 and headquartered in Munich, Germany, operating with a 1-10 employee team. The company is built on the discovery by co-founders Prof. em. Dr. Gabriele Multhoff and Dr. Claus Botzler that cell surface-bound (membrane) Hsp70 is uniquely expressed on approximately 50-75% of cancer cells but not on non-cancerous cells, making it a tumor-selective marker for a single theranostic approach applicable across multiple cancer types. The platform is led by CEO Prof. em. A. Graham Pockley and Founder/CSO Prof. em. Dr. Gabriele Multhoff.

The company has built three integrated product pipelines anchored on this marker: mi-THERAPEUTICS (ENKASTIM-ev ex vivo NK cell therapy, ENKASTIM-iv in vivo peptide therapy, mi-TPPtx targeting peptide, mi-TUMEXtx therapeutic monoclonal antibody, and mi-APO recombinant granzyme B); mi-DIAGNOSTICS (the Hsp70-exo companion diagnostic assay and the cmHsp70.1 monoclonal antibody for blood-based Hsp70 detection, patient identification, and circulating tumor cell isolation); and mi-IMAGING (mi-TPPim and mi-TUMEXim for PET/CT, fluorescence endoscopy, and intraoperative tumor imaging). Phase I and Phase II clinical trials of ENKASTIM-ev in NSCLC and colorectal cancer have been completed, with Phase II NSCLC data showing a 71% clinical benefit rate (5/7 patients) and median progression-free survival of 13 months versus 28% and 8 months in controls. The imaging agents and the Hsp70-exo companion diagnostic have USPTO or EPO patent protection.

multimmune operates an asset-light commercialization model based on out-licensing its technology platform and forming co-development partnerships with pharmaceutical companies rather than building internal sales infrastructure; the company states global out-licensing and co-development as its go-to-market. Revenue is expected to come from upfront payments, development milestones, and royalties on products commercialized by partners. To date the company has been funded by Bayern Kapital (Technology Investment Fund Bayern III), S-Refit AG/Sobera Capital, RAABE Asset Management, SilverSky LifeSciences, private investors, and non-dilutive public funding agencies, with specific amounts undisclosed. The company is pre-revenue.

Name

multimmune GmbH

Legal name

multimmune GmbH

Website

https://multimmune.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

1–10 employees

Short description

multimmune GmbH is a clinical-stage German biopharmaceutical company developing a proprietary membrane Hsp70-targeting platform spanning therapeutics, companion diagnostics, and imaging agents for broad-spectrum cancer theranostics, commercialized via out-licensing to pharmaceutical partners.

Ownership category

akta.pro rank

Headquarters

HQ city

Regensburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Distribution channels2 records

Marketing channels3 records

Core offering

multimmune GmbH develops a proprietary cancer theranostics platform based on membrane-bound heat shock protein 70 (Hsp70), a tumor-specific marker expressed on approximately 50–75% of cancer cells but not on healthy tissues. The company is building three integrated pipelines — mi-THERAPEUTICS (NK cell-based immunotherapies and targeting antibodies/peptides), mi-DIAGNOSTICS (companion diagnostics including enzyme immunoassays and the Hsp70-exo blood test), and mi-IMAGING (PET/CT and fluorescence imaging agents) — all unified by the same membrane Hsp70 targeting mechanism and intended for out-licensing or co-development with pharmaceutical partners.

Product overview

multimmune GmbH is a clinical-stage biopharmaceutical company that has developed a proprietary technology platform centered on membrane heat shock protein 70 (Hsp70) as a tumor-specific target expressed on 50–75% of cancers but absent on healthy cells. The company's product portfolio spans three integrated pipelines: (1) mi-THERAPEUTICS — ENKASTIM-ev (ex vivo NK cell activation), ENKASTIM-iv (in vivo NK cell activation), mi-TPPtx (targeting peptide), and mi-TUMEXtx (therapeutic monoclonal antibody); (2) mi-DIAGNOSTICS — mi-DIAGNOSTIC enzyme immunoassay and Hsp70-exo companion diagnostic (CDx) for patient identification and therapeutic monitoring, both built on the cmHsp70.1 monoclonal antibody; and (3) mi-IMAGING — mi-TPPim (imaging peptide) and mi-TUMEXim (imaging monoclonal antibody) for tumor-specific PET/CT and fluorescence imaging. The company also offers recombinant granzyme B (mi-APO) and a 14mer peptide (mi-TPP) as targeting tools. All products are unified by the same membrane Hsp70 targeting mechanism, enabling a broad theranostic approach applicable across multiple cancer types.

Differentiator

Problem solved

Functional benefit

Products and services

• ENKASTIM-ev Active cellular immunotherapy (ACI) employing ex vivo Hsp70-peptide (TKD) and interleukin-2 (IL-2) to stimulate a patient's own natural killer (NK) cells to target and kill membrane Hsp70-positive tumors and metastases; intended for oncology patients with Hsp70-positive solid tumors.
• ENKASTIM-iv In vivo NK cell stimulation therapy using a GMP-grade Hsp70-based synthetic 14-amino-acid peptide (TKD) administered intravenously to activate NK cells to recognize and kill membrane Hsp70-positive tumors and metastases.
• mi-TPPtx A proprietary 14mer peptide that specifically recognizes and binds to membrane Hsp70 on tumor cells, enabling direct targeting of tumors expressing the marker.
• mi-TUMEXtx A unique monoclonal antibody targeting membrane Hsp70 that induces antibody-dependent cellular cytotoxicity (ADCC) of Hsp70-positive tumors and metastases while sparing healthy cells.
• mi-DIAGNOSTIC (dx) Enzyme Immunoassay A patented enzyme immunoassay for detecting lipid-associated Hsp70 in the blood using multimmune's proprietary monoclonal antibodies, designed to identify patients who will respond to membrane Hsp70-directed therapies.
• Hsp70-exo Companion Diagnostic (CDx) A companion diagnostic assay quantifying 'free' and 'exosomal' Hsp70 levels in patient blood to detect tumors expressing membrane Hsp70 and monitor therapeutic response and disease recurrence (US patent granted; EPO application pending).
• cmHsp70.1 Monoclonal Antibody A monoclonal antibody recognizing the membrane form of Hsp70 expressed on cancer cells, used for identifying Hsp70 membrane-positive tumor phenotypes and for isolating circulating tumor cells (CTCs) after epithelial-to-mesenchymal transition.
• mi-TPPim A 14mer peptide-based imaging agent that selectively recognizes membrane Hsp70 on tumor cells, enabling tumor-specific PET/CT and fluorescence molecular endoscopy imaging (EPO patent granted).
• mi-TUMEXim A membrane Hsp70-specific monoclonal antibody providing a multimodal imaging platform for tumors and metastases, enabling improved diagnostic procedures and therapeutic monitoring; also serves as a platform for tumor-specific drug delivery.

Quantifiable outcome

• 71% clinical benefit rate (5/7 patients) vs 28% for standard of care in Phase II NSCLC trial
• +4 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• MacroGenics: Clinical-stage biotech developing therapeutic monoclonal antibodies and bispecifics for cancer, overlapping multimmune's mAb platform (mi-TUMEXtx) and oncology focus.
• Affimed: Clinical-stage biotech developing innate cell engagers, particularly NK cell and macrophage-engaging bispecific antibodies for oncology, paralleling multimmune's NK cell activation strategy.
• Innate Pharma: Clinical-stage biotech developing NK cell-based immunotherapies for cancer, including cell engagers and antibody platforms. Most directly comparable to multimmune on NK cell activation and oncology focus.
• Nkarta Therapeutics: Clinical-stage biotech engineering NK cell therapies for cancer, including both CAR-NK and NK cell engager approaches. Comparable stage, modality, and therapeutic area.
• GT Biopharma: Clinical-stage biotech developing NK cell engagers (TriKE platform) and other immuno-oncology candidates, similar in stage, mechanism class, and oncology focus.
• Kiadis Pharma: Clinical-stage biotech developing NK cell-based therapies for cancer and infectious diseases, directly comparable on modality, stage, and therapeutic area to multimmune's ENKASTIM programs.

Broad incumbents

• Nektar Therapeutics: Clinical-stage biotech with a broader immuno-oncology pipeline including cytokine-based therapies and NK cell engagers, providing a more diversified modality comparison.

Regional players

• Heidelberg Pharma: Germany-based clinical-stage biotech developing antibody-drug conjugates and targeted cancer therapies, comparable as a German oncology biotech at a similar development stage.

Emerging players

• CytomX Therapeutics: Clinical-stage biotech developing conditionally activated antibody therapies (Probody platform), comparable as a small-cap oncology antibody-focused biotech pursuing novel targeted approaches.
• F-star Therapeutics: Clinical-stage biotech developing bispecific antibodies using an Fc engineering platform, overlapping multimmune's antibody engineering modality though with different targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/multimmune-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about multimmune GmbH